Archive · 14 Aug 2025
Amansa Invests ₹250 Crore in Rubicon Research Pre-IPO Funding
A company called Rubicon Research, which makes medicines, is getting ready to sell shares to the public (IPO).
Before they do, a company called Amansa Investments gave them ₹250 crore.
This means Amansa bought some shares from one of Rubicon's owners, General Atlantic.
The money will help Rubicon pay off debt and grow.
Rubicon already has many medicines approved in the US and has more in development.
This investment is a step toward Rubicon becoming a publicly traded company, with the money going towards expansion and debt management.
Amansa Investments invested ₹250 crore in Rubicon Research through a pre-IPO funding round.
General Atlantic, a promoter of Rubicon Research, transferred 51.60 lakh equity shares to Amansa Investments.
The transaction was approved by the board on August 12 and conducted with the book running lead managers.
Rubicon Research plans to use the fresh issue proceeds for debt payment, inorganic growth, and other initiatives.
Rubicon Research has a portfolio of 69 USFDA-approved products as of March 31, 2024.
- Who
- Amansa Investments invested in Rubicon Research; General Atlantic transferred shares.
- What
- Amansa Investments invested ₹250 crore in Rubicon Research through a pre-IPO funding round.
- When
- The board approved the transaction on August 12, 2024, after the draft papers were filed in July 2024.
- Where
- The transaction involves the pharmaceutical company Rubicon Research.
- Why
- Rubicon Research will use the funds to pay debt, support growth, and for general corporate purposes.
- Investor
- Amansa Investments
- Investment Amount
- ₹250 crore
- Company
- Rubicon Research Ltd
- Share Price
- ₹484.47 per share
- Shares Transferred
- 51.60 lakh
- USFDA Approved Products
- 69
